丁苯酞联合神经节苷脂治疗急性脑梗死的临床疗效及对患者神经功能的影响

doi:10.3969/j.issn.1671-7171.2024.02.030

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1199 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨丁苯酞联合神经节苷脂治疗急性脑梗死(ACI)的临床疗效及其对患者神经功能的影响。【方法】选取2021年3月至2022年12月本院收治的98例ACI患者,采用随机数字表法将其分为对照组和观察组,每组49例。对照组采用神经节苷脂治疗,观察组采用丁苯酞联合神经节苷脂治疗。比较两组患者临床总有效率、相关评分[Barthel指数评定量表(BI)、脑卒中专用生活质量量表(SS-QOL)、美国国立卫生院卒中量表(NIHSS)]、神经功能指标[神经元特异性烯醇化酶(NSE)、中枢神经特异蛋白(S100β)、髓磷脂碱性蛋白(MBP)]水平、血流动力学指标[血全素黏度(WBV)、血浆黏度(FIB)、红细胞压积(HCT)、凝血因子(PV)]及血清血管内皮生长因子(VEGF)、氧化三甲胺(TMAO)、血栓素A2(TXA2)、内皮素1(ET-1)水平。【结果】观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者NIHSS评分低于治疗前,BI评分、SS-QOL评分高于治疗前,且观察组与对照组比较,差异有统计学意义(P<0.05);两组NSE、S100β及MBP水平均低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05);两组患者HCT、WBV、FIB及PV水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组血清VEGF水平高于治疗前,ET-1、TMAO、TXA2水平低于治疗前,且观察组与对照组比较,差异有统计学意义(P<0.05)。【结论】丁苯酞联合神经节苷脂治疗ACI疗效较好,促进神经功能恢复,提高患者生活质量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	鲁红利
	郑海静
	马琪

关键词 ：脑梗死/治疗, 急性病, 苯丙酮类/治疗应用, 神经节苷脂/治疗应用, 血管内皮生长因子类

Abstract：【Objective】To explore the clinical efficacy of the combination of butylphthalide and gangliosides in the treatment of acute cerebral infarction (ACI) and its impact on the neurological function of patients. 【Methods】A total of 98 ACI patients admitted to our hospital from March 2021 to December 2022 were selected and randomly divided into a control group and an observation group using a random number table method, with 49 cases in each group. The control group received treatment with gangliosides, while the observation group received treatment with a combination of butylphthalide and gangliosides. We compared two groups of clinical total effective rates, related scores [Barthel Index Rating Scale (BI), Stroke Specific Quality of Life Scale (SS-QOL), National Institutes of Health Stroke Scale (NIHSS)], neurological function indicators [Neuron Specific Enolase (NSE), Central Nervous System Specific Protein (S100β), Myelin Basic Protein (MBP)] levels, hemodynamic indicators(WBV, FIB) Blood cell hematocrit (HCT), coagulation factor (PV), and serum levels of vascular endothelial growth factor (VEGF), trimethylamine oxide (TMAO), thromboxane A2 (TXA2), and endothelin 1 (ET-1). 【Results】The total clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the NIHSS score of the two groups of patients was lower than before treatment, while the BI score and SS-QOL score were higher than before treatment. The difference between the observation group and the control group was statistically significant (P<0.05); The levels of NSE, S100β, and MBP in both groups were lower than before treatment, while the observation group was lower than the control group, and the difference was statistically significant (P<0.05); The levels of HCT, WBV, FIB, and PV in the two groups of patients were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05); The serum VEGF levels of the two groups were higher than before treatment, while the levels of ET-1, TMAO, and TXA2 were lower than before treatment. The difference between the observation group and the control group was statistically significant (P<0.05). 【Conclusion】The combination of butylphthalide and gangliosides has a good therapeutic effect on ACI, and improve the quality of life of patients.

Key words： Brain Infarction/TH Acute Disease Propiophenones/TU Gangliosides/TU Vascular Endothelial Growth Factors

收稿日期: 2023-06-07

中图分类号:

R743.33

引用本文:

鲁红利, 郑海静, 马琪. 丁苯酞联合神经节苷脂治疗急性脑梗死的临床疗效及对患者神经功能的影响[J]. 医学临床研究, 2024, 41(2): 265-268.
LU Hongli, ZHENG Haijing, MA Qi. The Clinical Efficacy of the Combination of Butylphthalide and Gangliosides in the Treatment of Acute Cerebral Infarction and its Impact on the Neurological Function of Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 265-268.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.02.030 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I2/265

[1] 俞梁,杨越,楼晶晶,等.银杏达莫注射液联合丁苯酞氯化钠注射液治疗急性脑梗死患者的临床研究[J].中国临床药理学杂志,2022,39(4):459-463.
[2] 李泳祺.阿司匹林联合神经节苷脂治疗脑梗死的临床疗效分析[J].中国实用医药,2020,16(18):96-98.
[3] 陈冲,林秋,邱桂森.丁苯酞治疗脑梗死伴认知功能障碍的临床疗效观察[J].中西医结合心脑血管病杂志,2021,20(10):1879-1882.
[4] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国全科医学,2011,14(35):4013-4017.
[5] 段萍,田鹏飞.丁苯酞氯化钠治疗急性脑梗死伴认知功能障碍的临床效果[J].实用中西医结合临床,2021,22(23):51-53.
[6] 王洋,李高华,王胜英,等.急性脑梗死不同神经功能缺损评分患者的心率变异性各参数差异及早期药物干预效果对比[J].中国医师杂志,2020,23(7):1086-1089.
[7] 王柳毅,刘文慧,崔琼.脑心通胶囊治疗急性脑梗死患者疗效及对细胞炎症因子、凝血功能和血液流变学的影响观察[J].贵州医药,2020,45(11):1739-1740.
[8] 石小翠,胡美云,杜寨,等.神经节苷脂注射液联合依达拉奉注射液治疗未溶栓急性脑梗死患者的效果观察及对认知功能、日常生活能力的影响[J].解放军医药杂志,2020,33(9):101-105.
[9] 刘明月,胡建荣,姜晋灵.丁苯酞联合吡拉西坦对脑卒中后认知功能障碍患者认知功能及脑内神经递质水平的影响[J].国际精神病学杂志,2021,49(2):271-274.
[10] 朱晓峰.血清NSE、MBP水平对老年脑梗死患者神经功能康复的预测价值分析[J].检验医学与临床,2020,18(11):1619-1621.
[11] 刘霞,陶彦春,王娜,等.神经介入溶栓术治疗急性脑梗死的临床疗效及对患者血清NSE、S-100β及神经生长因子的影响[J].海南医学,2020,32(11):1384-1387.
[12] 刘赵东,岳金利,李映霞.血塞通联合阿替普酶治疗急性脑梗死的疗效及对血清ET-1、TXA2水平影响[J].中华中医药学刊,2021,40(8):213-216.
[13] 穆永芳,郭永力,蒋召芹,等.阿替普酶治疗急性脑梗死患者的疗效、血清ET-1、TXA2水平及不良反应影响[J].湖南师范大学学报(医学版),2021,19(2):208-211.
[14] GUASTI L,GALLIAZZO S,MOLARO M,et al.TMAO as a biomarker of cardiovascular events:A systematic review and metaanalysis[J].Int Emerg Med,2021,16(1):201-207.
[15] 杨东娜,张涤,于佳佳.丁苯酞注射液联合依达拉奉对老年急性脑梗死患者细胞因子、血管内皮功能和氧化应激的影响[J].中国老年学杂志,2020,41(3):477-480.